Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by William Blair Investment Management LLC

William Blair Investment Management LLC grew its stake in Twist Bioscience Co. (NASDAQ:TWST) by 76.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,615,798 shares of the company’s stock after buying an additional 1,561,277 shares during the period. William Blair Investment Management LLC owned 6.30% of Twist Bioscience worth $73,979,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Los Angeles Capital Management LLC boosted its holdings in shares of Twist Bioscience by 17.4% in the 2nd quarter. Los Angeles Capital Management LLC now owns 13,582 shares of the company’s stock valued at $278,000 after buying an additional 2,012 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of Twist Bioscience by 427.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,818,153 shares of the company’s stock valued at $37,199,000 after buying an additional 1,473,632 shares in the last quarter. LPL Financial LLC boosted its holdings in shares of Twist Bioscience by 44.0% in the 2nd quarter. LPL Financial LLC now owns 39,107 shares of the company’s stock valued at $800,000 after buying an additional 11,953 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Twist Bioscience by 1.0% in the 2nd quarter. Fisher Asset Management LLC now owns 785,457 shares of the company’s stock valued at $16,070,000 after buying an additional 8,081 shares in the last quarter. Finally, Candriam S.C.A. boosted its holdings in shares of Twist Bioscience by 8.1% in the 2nd quarter. Candriam S.C.A. now owns 334,360 shares of the company’s stock valued at $6,841,000 after buying an additional 25,000 shares in the last quarter.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $24.70 on Tuesday. The company has a market cap of $1.42 billion, a P/E ratio of -6.69 and a beta of 1.32. Twist Bioscience Co. has a one year low of $11.46 and a one year high of $31.51. The firm has a fifty day moving average of $18.72 and a two-hundred day moving average of $19.20.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, November 17th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. The company had revenue of $66.95 million during the quarter, compared to the consensus estimate of $63.35 million. Twist Bioscience had a negative net margin of 88.97% and a negative return on equity of 29.09%. Twist Bioscience’s quarterly revenue was up 16.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.91) EPS. As a group, equities analysts predict that Twist Bioscience Co. will post -3.73 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Barclays upped their target price on shares of Twist Bioscience from $20.00 to $26.00 and gave the company an “overweight” rating in a report on Monday, August 7th. Berenberg Bank began coverage on shares of Twist Bioscience in a research report on Wednesday, September 27th. They issued a “buy” rating and a $27.00 price target for the company. Finally, Robert W. Baird upped their price target on shares of Twist Bioscience from $18.00 to $27.00 in a research report on Monday, August 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $28.43.

Twist Bioscience Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.